To compare p16 overexpression in ULMSs and leiomyomas or smooth muscle tumors of uncertain malignant potential, O’Neill et al assessed the p16 immunohistochemical expression in a variety of uterine smooth muscle tumors. This evidence concerns the gene CDKN2A and smooth muscle tumor.